drugset / Trial / NCT03991936

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

NCT03991936

Phase 4 Completed 11 enrolled Weill Medical College of Cornell University
RandomizedParallel-groupDouble-blindTreatment

Summary

This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.

Timeline

Start
2020-03-11
Primary completion
2023-03-29
Completion
2023-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 2.5 mg/ml Other
Subject Triamcinolone Acetonide Other / unclassified 5 mg/ml Other
Subject Triamcinolone Acetonide Other / unclassified 7.5 mg/ml Other
Subject Triamcinolone Acetonide Other / unclassified 10 mg/ml Other

Indications